Bone turnover assessment: a good surrogate marker?
To asses fracture risk, bone mineral density (BMD) measured by dual-energy X-ray absorptiometry (DXA) is the most commonly used tool. The search for clinical risk factors is also advised and can provide a 10-year fracture probability (FRAX model). Another important determinant of bone strength is bone remodeling. High bone remodeling rates have been associated with a higher fracture risk and bone turnover markers (BTM) may offer dynamic information about skeletal status independent of BMD. The efficacy of antiresorptive agents in fracture prevention goes beyond what can be predicted by BMD especially in the beginning of the treatment. Inhibition of bone remodeling itself is certainly an important mechanism by which antiresorptive agents can rapidly reduce fracture risk. Thus, it seems quite logical to use BTM in patients with bone disease. It can also become a valuable surrogate marker in fracture prediction. However, BTM's pre-analytical and analytical variability should always be considered.
Dreyer
Patrícia
P
Unidade de Metabolismo Osseo e Mineral, Universidade Federal de São Paulo, SP, Brasil. patricia.dreyer@fleury.com.br
Vieira
José Gilberto H
JG
D015415:Biomarkers / Q000097:blood*; D015519:Bone Density; D016723:Bone Remodeling / Q000502:physiology*; D001842:Bone and Bones; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D010024:Osteoporosis / Q000097:blood* / Q000150:complications / Q000628:therapy
D015415:Biomarkers